Literature DB >> 30344756

CHSY1 promoted proliferation and suppressed apoptosis in colorectal cancer through regulation of the NFκB and/or caspase-3/7 signaling pathway.

Lifeng Zeng1, Jinrong Qian2, Xiaojiang Luo3, Aiqun Zhou1, Zhiyong Zhang1, Quangang Fang1.   

Abstract

Colorectal cancer is a commonly observed malignant cancer. However, the limited therapies for colorectal cancer do not bring much benefit for patients. Chondroitin synthase-1 (CHSY1) is an enzyme responsible for the biosynthesis of chondroitin sulfate and has been implicated in the tumorigenesis of several cancer types; however, there is limited information regarding the role of CHSY1 in colorectal cancer. In the present study, CHSY1 was demonstrated to be highly expressed in colorectal cancer tissues and in cell lines, and the CHSY1 expression level was associated with the 5-year survival rate of patients with colorectal cancer. Following CHSY1 knockdown, the proliferation of colorectal cancer cells was significantly decreased. The number of RKO cells decreased by 50% following CHSY1 knockdown compared with that in the control after culture for 5 days. However, the apoptosis rate of RKO cells increased to 14.15% after CHSY1 knockdown. In addition, the activity of caspase-3/7 was also enhanced. Furthermore, the expression of B-cell lymphoma 2 (Bcl-2) was reduced, whereas the levels of Bcl-2-associated X protein (Bax) and truncated caspase-3/7 were increased following CHSY1 knockdown. Additionally, the phosphorylation level of IκB and the expression of nuclear factor (NF)κB also decreased. In contrast, forced expression of CHSY1 increased the level of Bcl-2, NFκB, and phosphorylated IκB, whereas the level of bax and truncated caspase-3/7 decreased. Therefore, the data of the present study suggest that CHSY1 promoted cell proliferation by regulating NFκB signaling and suppressed cell apoptosis by regulating/caspase-3/7 signaling in colorectal cancer. The present study also suggests that CHSY1 may be a potential target for colorectal cancer therapy.

Entities:  

Keywords:  CHSY1; NFκB; RKO cell line; caspase-3/7; chondroitin sulfate

Year:  2018        PMID: 30344756      PMCID: PMC6176353          DOI: 10.3892/ol.2018.9385

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  29 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Apoptosis: mechanisms and relevance in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Ann Hematol       Date:  2005-07-22       Impact factor: 3.673

3.  Loss of CHSY1, a secreted FRINGE enzyme, causes syndromic brachydactyly in humans via increased NOTCH signaling.

Authors:  Jing Tian; Ling Ling; Mohammad Shboul; Hane Lee; Brian O'Connor; Barry Merriman; Stanley F Nelson; Simon Cool; Osama H Ababneh; Azmy Al-Hadidy; Amira Masri; Hanan Hamamy; Bruno Reversade
Journal:  Am J Hum Genet       Date:  2010-12-10       Impact factor: 11.025

4.  Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.

Authors:  Devendra S Dandekar; Monica Lopez; Robert I Carey; Bal L Lokeshwar
Journal:  Int J Cancer       Date:  2005-06-20       Impact factor: 7.396

5.  Chondroitin synthases I, II, III and chondroitin sulfate glucuronyltransferase expression in colorectal cancer.

Authors:  Dimitrios Kalathas; Dimitrios A Theocharis; Dimitrios Bounias; Dora Kyriakopoulou; Nikoletta Papageorgakopoulou; Michael S Stavropoulos; Demitrios H Vynios
Journal:  Mol Med Rep       Date:  2011-01-25       Impact factor: 2.952

6.  Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.

Authors:  Rolf Sauer; Torsten Liersch; Susanne Merkel; Rainer Fietkau; Werner Hohenberger; Clemens Hess; Heinz Becker; Hans-Rudolf Raab; Marie-Therese Villanueva; Helmut Witzigmann; Christian Wittekind; Tim Beissbarth; Claus Rödel
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  Chondroitin synthase 1 is a key molecule in myeloma cell-osteoclast interactions.

Authors:  Larry Yin
Journal:  J Biol Chem       Date:  2004-10-13       Impact factor: 5.157

Review 9.  Cartilage in normal and osteoarthritis conditions.

Authors:  Johanne Martel-Pelletier; Christelle Boileau; Jean-Pierre Pelletier; Peter J Roughley
Journal:  Best Pract Res Clin Rheumatol       Date:  2008-04       Impact factor: 4.098

10.  Chondroitin sulfate synthase-2 is necessary for chain extension of chondroitin sulfate but not critical for skeletal development.

Authors:  Hiroyasu Ogawa; Sonoko Hatano; Nobuo Sugiura; Naoko Nagai; Takashi Sato; Katsuji Shimizu; Koji Kimata; Hisashi Narimatsu; Hideto Watanabe
Journal:  PLoS One       Date:  2012-08-28       Impact factor: 3.240

View more
  10 in total

1.  FOXM1-Activated LINC01094 Promotes Clear Cell Renal Cell Carcinoma Development via MicroRNA 224-5p/CHSY1.

Authors:  Yufeng Jiang; Haimin Zhang; Wei Li; Yang Yan; Xudong Yao; Wenyu Gu
Journal:  Mol Cell Biol       Date:  2020-01-16       Impact factor: 4.272

2.  LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis.

Authors:  Luotong Liu; Qian Xu; Yu Xiong; Huajiang Deng; Jie Zhou
Journal:  Hum Cell       Date:  2021-10-30       Impact factor: 4.174

3.  CHSY1 is upregulated and acts as tumor promotor in gastric cancer through regulating cell proliferation, apoptosis, and migration.

Authors:  Jingjing Liu; Zhenwei Tian; Tianzhou Liu; Dacheng Wen; Zhiming Ma; Yuanda Liu; Jiaming Zhu
Journal:  Cell Cycle       Date:  2021-08-19       Impact factor: 5.173

4.  Chondroitin sulfate synthase 1 enhances proliferation of glioblastoma by modulating PDGFRA stability.

Authors:  Wen-Chieh Liao; Chih-Kai Liao; To-Jung Tseng; Ying-Jui Ho; Ying-Ru Chen; Kuan-Hung Lin; Te-Jen Lai; Chyn-Tair Lan; Kuo-Chen Wei; Chiung-Hui Liu
Journal:  Oncogenesis       Date:  2020-02-04       Impact factor: 7.485

5.  Adipose-Derived Stem Cells Inhibited the Proliferation of Bladder Tumor Cells by S Phase Arrest and Wnt/β-Catenin Pathway.

Authors:  Tao Wang; Xi Yu; Jian Lin; Cong Qin; Tao Bai; Tao Xu; Lei Wang; Xiuheng Liu; Shenglan Li
Journal:  Cell Reprogram       Date:  2019-12       Impact factor: 1.987

Review 6.  Versatile Types of Polysaccharide-Based Drug Delivery Systems: From Strategic Design to Cancer Therapy.

Authors:  Yanzhen Sun; Xiaodong Jing; Xiaoli Ma; Yinglong Feng; Hao Hu
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

7.  LncRNA LHFPL3-AS1 Promotes Oral Squamous Cell Carcinoma Growth and Cisplatin Resistance Through Targeting miR-362-5p/CHSY1 Pathway.

Authors:  Jiandong Li; Xiaohu Xu; Dandan Zhang; Han Lv; Xin Lei
Journal:  Onco Targets Ther       Date:  2021-03-31       Impact factor: 4.147

Review 8.  LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma.

Authors:  Eleonora A Braga; Marina V Fridman; Elena A Filippova; Vitaly I Loginov; Irina V Pronina; Alexey M Burdennyy; Alexander V Karpukhin; Alexey A Dmitriev; Sergey G Morozov
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

9.  Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory.

Authors:  Maike Stahlhut; Teng Cheong Ha; Ekaterina Takmakova; Michael A Morgan; Adrian Schwarzer; Dirk Schaudien; Matthias Eder; Axel Schambach; Olga S Kustikova
Journal:  Sci Rep       Date:  2021-03-05       Impact factor: 4.379

10.  Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer.

Authors:  Karina Biskup; Caroline Stellmach; Elena Ioana Braicu; Jalid Sehouli; Véronique Blanchard
Journal:  Diagnostics (Basel)       Date:  2021-06-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.